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Cell proliferation and cell growth are two tightly linked processes, as the proliferation program
cannot be executed without proper accumulation of cell mass, otherwise endangering the fate of
the two daughter cells. It is therefore not surprising that ribosome biogenesis, a key element in cell
growth, is regulated by many cell cycle regulators. This regulation is exerted transcriptionally and
post-transcriptionally, in conjunction with numerous intrinsic and extrinsic signals. Those signals
eventually converge at the nucleolus, the cellular compartment that is not only responsible for
executing the ribosome biogenesis program, but also serves as a regulatory hub, responsible for
integrating and transmitting multiple stress signals to the omnipotent cell fate gatekeeper, p53.
In this review we discuss when, how and why p53 is activated upon ribosomal biogenesis stress,
and how perturbation of this critical regulatory interplay may impact human disease.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction regulators? The basic explanation is actually rather simple. CancerTransformation of normal cells into cancer cells requires dys-
regulated activity of oncogenes that drive cellular proliferation
and survival, alter metabolism and promote invasion into adjacent
tissue. Additionally, neoplastic transformation requires inactiva-
tion, through mutations, deletions or epigenetic silencing, of tumor
suppressor genes that monitor cell homeostasis, block unsched-
uled proliferation and prevent illegitimate cell survival.
When considering cellular pathways regulated by oncogenes
and tumor suppressors, it is not immediately obvious that ribo-
some biogenesis should be among those pathways. However, a sig-
niﬁcant body of evidence accumulated over the last 10–15 years
suggests that alterations of one or more steps that control ribo-
some biogenesis are essential for malignant transformation and
progression, as many key tumor suppressors and proto-oncogenes
have been found to regulate this process (Table 1). Among them,
c-MYC and the components of the PI3K-mTORC1 signaling path-
way are emerging as key regulators of ribosome biogenesis. So
why exactly is a seemingly innocuous process found in the midst
of a battleground between powerful positive and negative cellularis characterized by uncontrolled proliferation of cells, occurring
relatively independently of external stimuli [1]. Yet, cell prolifera-
tion cannot take place without proper cell growth, namely an
increase in cell mass. The increment in cell mass requires extensive
protein synthesis, which is dependent on a constant supply of new
ribosomes, effectively coupling ribosome biogenesis and protein
synthesis to the cell cycle [2]. This is presumably the reason why
genes like c-MYC, which control cell cycle progression and DNA
synthesis, have evolved to also coordinate ribosome biogenesis
and protein biosynthesis [3]. While c-MYC evolved to promote cell
proliferation and growth, both under normal conditions and as a
driver of malignancy, tumor suppressors like p53 and ARF, one of
the two products of the INK4a locus, co-evolved as inspectors of
cell homeostasis and emerged as gatekeepers of both genomic
integrity and ribosome biogenesis.
Reﬂected by the large number of factors that regulate ribosome
biogenesis, the construction of new ribosomes is an elaborate,
well-coordinated process, and extremely demanding in terms of
energy and resources [4]. It requires the activity of all three RNA
polymerases, in order to transcribe both the rRNA and the mRNAs
encoding about 80 distinct integral ribosomal proteins (RPs) and
other accessory proteins. Ribosome biogenesis also impinges heav-
ily upon the translation apparatus [4] and the nuclear import/
export machinery [5,6].
Within the cell, the nucleolus is the main site of ribosome bio-
genesis (Fig. 1A). It is a sub-nuclear compartment where clusters of
Table 1
A list of reported participants in ribosome biogenesis stress signaling (upper) and key
regulators of ribosome biogenesis (lower).
Activators of p53 following ribosome biogenesis stress
Ribosomal proteins RPL5 [65], RPL11 [64], RPL23 [66,128], RPS7 [129],
RPL26 [91,92], RPS14 [96], RPS3 [130], RPL37 [131],
RPS15 [131], RPS20 [131], RPS26 [132], RPS27
[133], RPS27L [133], RPS25 [134]
RNA 5S rRNA [84–86]
Accessory factors PICT1 [88], nucleostemin [135], SRSF1 [89] NPM
[136], NCL [93,137]
Regulators of ribosome biogenesis
Oncogenic pathways c-MYC (reviewed in [3]), E2F [138], AKT [139],
mTOR (reviewed in [140]), ERK (reviewed in [11])
Tumor suppressors p53 (reviewed in [10,11]), ARF (reviewed in [115]),
PTEN [141], pRB (reviewed in [11])
2572 L. Golomb et al. / FEBS Letters 588 (2014) 2571–2579tandem repeats of rRNA genes are organized into what is known as
nucleolar organizing regions (NOR). The rRNA genes are tran-
scribed by RNA polymerase I (PolI) to produce the precursor 47S
rRNA with concurrent processing into mature rRNA species [7],
followed by assembly of the rRNA together with RPs to form the
40S and 60S ribosomal subunits (Fig. 1A). Notably, different steps
of the ribosome biogenesis process are misregulated in a variety
of human malignancies, including cancer. A growing number of
reports uncover a more complicated picture, where altered activity
of the ribosome biogenesis machinery is not merely required to
support the rapid proliferation of neoplastic cells, but it might also
serve as a driving force in malignancy [8,9]. Thus, the activity of
RNA PolI is dysregulated in cancer and other human pathologies
[10,11], and enhanced rRNA transcription might attenuate the
activity of tumor suppressor genes [8]. In addition to excessive
RNA PolI activity, many RPs are overexpressed in human tumors
such as colorectal cancer [12,13], esophagus cancer [14] and40S
RPS
RPS
RPS
RPS
60S
RPL
RPL
RPL
RPL
Nucleolus
Mdm2
p53
ub
ub
ub
ub
Nucleoplasm
Cytoplasm
40S
RPS
40S
RPS
40S
RPS
60S
RPL
60S
RPL
60S
RPL
40S
RPS
60S
RPL
40S
RPS
60S
RPL
proteasomal
degradation
A
Transcription
Processing
Assembly
rDNA
Large subunit RP
Small subunit RP
Exportin 1
60S subunit
40S subunit
Importin
Nuclea
Proteas
IPO7
IPO
IPO
IPO
IPO
Fig. 1. An overview of ribosome biogenesis, both under normal and stress conditions. (A)
imported into the nucleolus, where they are assembled together with processed rRNA in
p53 and polyubiquitylates it, sending it to proteasomal degradation, possibly assisted by
can cause unassembled RPs and 5S rRNA to bind Mdm2 and prevent p53 degradation.hepatocellular carcinoma [15]. Cancer cells might beneﬁt from
the dysregulation of speciﬁc RPs expression, as this might alter
quality or quantity of the synthesized tumor promoting proteins
[9] or even provide some non-ribosomal advantageous features
[16].
Remarkably, alongside its role as the hub of ribosome biogene-
sis, the nucleolus also evolved into a highly sensitive regulatory
hub, which is able to sense various stress signals and initiate a
plethora of signaling cascades [17]. Of particular interest is a newly
recognized signaling pathway involving ribosomal proteins RPL11
and RPL5 as well as 5S rRNA, which has a unique role in conveying
stress messages upon impairment of ribosome biogenesis directly
to the Mdm2/p53 module [18]. In this review we describe how
the nucleolus and the ribosome biogenesis apparatus serve as
unique transmitters of multiple stress signals, which impinge on
the tumor suppressor transcription factor p53. We summarize
the current knowledge regarding the mechanisms of p53 activation
following ribosomal stress, and discuss how malfunctions in the
ribosome biogenesis machinery can promote tumorigenesis and
how this knowledge might be harnessed towards improving cancer
therapy.
2. The nucleolus as a stress sensor
Because the process of ribosome biogenesis is extremely
demanding in terms of energy and resources, its ﬁdelity is closely
inspected and virtually any type of severe cellular stress will result
in an immediate shutdown of rRNA transcription (Fig. 1B) [19]. In
response to such stress conditions, including exposure to different
genotoxic agents like doxorubicin or inhibition of rRNA transcrip-
tion using low levels of Actinomycin D (ActD), the nucleolus under-
goes distinct structural changes, including condensation and
segregation into structures called nucleolar caps, composed of
nucleolar proteins and RNA [17,20,21]. Consequently, detection40S
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Under basal conditions, rRNA is transcribed and processed in the nucleolus. RPs are
to the large and small ribosomal subunits (60S and 40S, respectively). Mdm2 binds
nucleolar-mediated export. (B) Inhibition of different steps in ribosome biogenesis
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severe nucleolar stress. In other cases of milder stress, for example
when ribosome biogenesis is suppressed by depletion of Rps6,
nucleolar morphology is not distinctly altered [22]. Of note, many
types of cellular stress, including Hypoxia [23], heat shock [23] and
growth factor deprivation [24], were reported to activate p53 by
blocking different steps of ribosome biogenesis and inducing
nucleolar stress (Fig. 1B).
DNA damage has long been known to activate p53 through a
variety of mechanisms [25,26], yet a revolutionary concept was
proposed by Rubbi and Milner [23]. In a vintage experiment they
showed that directed DNA damage, using localized UV irradiation,
failed to activate p53 when the nucleolus remained unaffected,
leading them to conclude that DNA damage alone cannot activate
p53 and that nucleolar disruption is a prerequisite for p53 activa-
tion. However, future research will be necessary to uncover the
underlying mechanisms by which DNA damage inhibits various
steps of ribosome biogenesis and understand how various signal-
ing pathways triggered by this type of stress are coordinated dur-
ing p53 activation.
The ﬁrst demonstration of a direct connection between
p53-dependent cell cycle arrest and inhibition of ribosome biogen-
esis was provided by Pestov and colleagues [27], who showed that
expression of a dominant negative form of Bop1, an rRNA matura-
tion factor, blocks rRNA processing and activates p53-dependent
growth arrest. Additional experimental models were subsequently
employed to examine the activation of p53 following attenuation
of ribosome biogenesis at multiple stages, such as by inhibition
of rRNA transcription following the knockout of TIF-1A [28] or
the transient knockdown of RNA PolI catalytic subunit POLR1A
[29]. A p53 response can also be elicited by blocking rRNA process-
ing or ribosome subunit assembly, through the stable or transient
knockdown of many RPs or ribosomal accessory proteins [18]. Fur-
thermore, ribosomal biogenesis is regulated not only at the stages
of biosynthesis and assembly of its various components. Ribosomal
proteins are synthesized in the cytoplasm, imported into the
nucleus for assembly in the nucleolus, and then exported back into
the cytoplasm as mature ribosomal subunits (Fig. 1A). This places
substantial demands on the nuclear import and export machiner-
ies, particularly in light of the large amounts of ribosome-relevant
cargo. Perturbation of nuclear import/export can therefore also eli-
cit ribosomal biogenesis stress. Indeed, creating imbalance in the
nuclear import of RPs through the knockdown of a single nuclear
import factor, Importin 7 (IPO7), sufﬁces to trigger p53 activation;
this activation is dependent on RPL5 and RPL11, conﬁrming that it
emerges through bona ﬁde ribosome biogenesis stress (Fig. 1B)
[30]. The molecular mechanisms by which these perturbations of
ribosome biogenesis trigger the p53 response will be discussed
below.
3. Activation of p53 upon impairment of ribosome biogenesis
in vivo
What are the in vivo manifestations of ribosomal stress-depen-
dent activation of p53? As the ﬁrst example, deletion of one mouse
Rps6 allele in the T cell lineage prevented proliferation of those
cells following receptor stimulation and reduced their accumula-
tion in the spleen and lymph nodes [31], an effect that was medi-
ated by p53. Furthermore, whole body deletion of a single Rps6
allele resulted in embryonic lethality during gastrulation, appar-
ently due to a p53-dependent checkpoint being triggered, as cross-
breeding with a p53-null mouse strain bypassed their lethality and
allowed their development until mid-gestation, when they most
likely died as a result of defective translation of speciﬁc mRNAs
[32]. More recently, the role of p53 in a number of mouse modelsfor RP deﬁciencies has been demonstrated, both in preventing and
mediating speciﬁc pathological manifestations [18].
Impairment of ribosome biogenesis is emerging as an important
cause of human diseases. Mutations and deletions of several genes
encoding RPs and ribosome biogenesis factors were found to
underlie a group of congenital disorders known as ribosomopa-
thies [33]. Diamond-Blackfan anemia (DBA) is the paradigm for
this type of disorders. DBA is characterized by hypoplastic macro-
cytic anemia and speciﬁc developmental defects [34]. DBA patients
are predisposed to the development of myelodysplastic syndrome
(MDS) as well as acute myeloid leukemia and solid malignancies
[35]. The most common genetic alterations in DBA are found
within the RPS19 gene, but mutations and deletions were also
found within several other RP genes [33,36]. Hapoloinsufﬁciencies
of RPS14 and RPSA were also identiﬁed in the 5q- syndrome, an
acquired somatic deletion of chromosome 5q [37], and isolated
congenital asplenia [38], respectively. Mutations in several other
ribosome biogenesis factors have been identiﬁed as causes of ribo-
somopathies, including the Schwachman–Diamond syndrome
(SDS), Treacher-Collins syndrome, dyskeratosis congenita and car-
tilage hair hypoplasia [39]. Recent studies of animal models of
ribosomopathies and patients with ribosomopathies support a role
for p53 in mediating speciﬁc pathological manifestations of these
disorders [18]. Both zebraﬁsh and mouse models of DBA revealed
a role for p53 in the erythroid deﬁciency, and p53 deletion was
found to rescue the erythroid phenotype in both these animal
models [40,41]. Recent evidence suggests that activation of p53
underlies the pathogenesis of the human DBA, 5q- syndrome and
SDS, as accumulation of nuclear p53 was found in bone marrow
biopsy samples from these patients. Knockdown of RPS19 or
RPS14 in human hematopoietic progenitor cells, mimicking com-
mon alterations in DBA and 5q- syndrome, respectively, was found
to selectively activate p53 in the erythroid lineage, probably due to
a lower threshold required for p53 activation in this lineage [42].
Importantly, lenalidomide, a common drug used to treat both
DBA and 5q- syndrome, was recently shown to exert its therapeu-
tic power through the inhibition of p53 [43]. However, the
molecular mechanisms whereby p53 mediates the ribosomal bio-
genesis stress checkpoint pathway in ribosomopathies remain to
be elucidated.
4. Mechanisms of p53 activation following ribosome biogenesis
stress
How is p53 activated following ribosome biogenesis stress? In
order to address this question, it is necessary to brieﬂy discuss
the mechanisms of p53 regulation by other types of stress signals.
In unstressed cells, p53 levels are typically very low. These low lev-
els are maintained in great part through the activity of p53’s E3
ubiquitin ligase Mdm2 [44]. Mdm2 and p53 form a negative feed-
back loop, in which p53 positively regulates the transcription of
theMdm2 gene, while Mdm2 in turn ubiquitylates p53 and thereby
promotes its proteasome-mediated degradation [45–47]. This
activity was proposed to require the shuttling of the p53/Mdm2
complex into the cytoplasm, where both proteins are degraded
by the proteasome, although subsequent reports indicate that pro-
teasome-mediated p53 degradation can also take place in the
nucleus [48,49], and even in the nucleolus in a ubiquitin-indepen-
dent, calpain-dependent manner [50]. Additionally, Mdm2 binds
the N-terminus of p53, blocking its transcriptional activity. In order
to activate p53, this loop must be interrupted. One way for this to
happen is through post-translational modiﬁcations (PTMs) such as
phosphorylation [51,52] and acetylation [53,54] of p53 as well as
Mdm2 [55,56]. These modiﬁcations impair p53/Mdm2 interaction
and enhance p53 tetramerization and its binding to p53 responsive
2574 L. Golomb et al. / FEBS Letters 588 (2014) 2571–2579elements within the DNA. The result of p53 activation will usually
depend on the context and severity of the imposed stress. For
example, while mild DNA damage might trigger p53-dependent
growth arrest and promote DNA repair, severe damage will often
result in either p53-dependent cellular senescence or apoptosis.
PTMs of p53 are not the only route to p53 activation. Another
way to disengage p53 from the deadly grip of Mdm2 is through
binding of modulator proteins to Mdm2, in a way that either
directly prevents Mdm2-p53 binding or sequesters Mdm2 in a dif-
ferent cellular compartment [57]. The best example is provided by
ARF. This potent tumor suppressor protein accumulates upon
excessive mitogenic signaling such as c-MYC overexpression, and
induces p53-dependent apoptosis or growth arrest [58]. Mechanis-
tically, ARF activates p53 by blocking Mdm2 function through its
ability to bind the acidic domain of Mdm2 [59,60] and hinder its
E3 ubiquitin ligase activity.
In a similar fashion to ARF, a number of RPs were found to bind
Mdm2 and activate p53. The ﬁrst indication that ribosomal ele-
ments can communicate directly with the p53 pathway was pro-
vided more than 20 years ago, when the 5.8S rRNA was reported
to be covalently linked to p53 [61,62]. This was followed by the
demonstration that the L5/5S rRNA complex can be co-immuno-
precipitated with Mdm2 and p53 [63]. The functional impact of
this interaction was unknown at the time, and it was speculated
that the L5/5S rRNA/p53-Mdm2 complex might participate in ribo-
some biogenesis control or alternatively may selectively block the
translation of speciﬁc, cell cycle-related mRNAs [63].
The fact that RPs can regulate p53 activity in a similar fashion to
ARF was ﬁrst demonstrated for RPL5, RPL11 and RPL23 [64–66].
Since then, many other RPs were reported to bind to Mdm2 and eli-
cit a p53 response in a similar fashion (Fig. 2A and Table 1). Over-
expression of RPL11, RPL5 and RPL23 was found to impede Mdm2
ubiquitin ligase activity and stabilize p53. Additionally, treatment
of cells with low levels of ActD, speciﬁcally inhibiting ribosome
biogenesis, was shown to increase the binding of RPL5 and RPL11
to Mdm2. Somewhat similar to ARF, the binding of the different
RPs was mapped to the central domain of Mdm2, yet to a slightly
different region than ARF [67]. Speciﬁcally, it was demonstrated
that a cancer-associated mutation causing a cysteine to phenylala-
nine substitution at position 305 within the Mdm2 zinc ﬁnger
domain (Mdm2C305F), located downstream to the central acidic
domain, is sufﬁcient to abort the interaction of Mdm2 with L5
and L11 and the subsequent p53 activation [68].
As mentioned above, many oncogenes and oncogenic pathways
that promote ribosome biogenesis (Table 1) can also trigger aRPS
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Following depletion of the 40S subunit, RPL11 mRNA translation in a 50TOP-dependent
Subsequent to ribosome biogenesis stress, newly synthesized RPL5 and RPL11 are import
the nucleus and are quickly degraded.potent p53 response [58,69,70]. Among these, c-MYC and RAS are
probably the most conspicuous. RAS is now believed to exert its
effect on p53 primarily through DNA replication stress and a
DNA damage response [71,72], although additional mediators such
as the tumor suppressors ARF [58,73] and Lats2 also contribute to
RAS-induced p53 activation [74]. In contrast, ARF was suggested to
be the main mediator of p53 activation following c-MYC overex-
pression [58]. However, this inference is challenged by the analysis
of mice expressing the Mdm2C305F mutant, crossbred with El-myc
mice. Notably, development of lymphoma in this c-MYC overex-
pression model was accelerated independently of ARF [75],
suggesting that excessive production of RPL5 and RPL11 when
c-MYC is hyperactive triggers the RPL5/RPL11/Mdm2/p53 ribo-
somal stress checkpoint signaling pathway to prevent malignant
transformation and tumor progression. Using the same Mdm2C305F
mouse model, it was subsequently found that in contrast to c-MYC
deregulation, the p53 response was not hampered when RAS was
overexpressed [76]. This is particularly intriguing in light of the
dogma that ARF is the main activator of p53 in the face of deregu-
lated c-MYC, but might be less important for RAS-dependent p53
activation in the human context [77].
The list of the RPs whose deregulation may promote p53 activa-
tion is still growing, but two of those RPs, RPL5 and RPL11, seem to
have a unique and exclusive role in p53 regulation following ribo-
some biogenesis stress. It is important to note that knockdown of
either RPL11 or RPL5 separately results in abrogation of an adequ-
ete p53 response in face of several ribosome biogenesis stress sig-
nals. Interestingly, knockdown of many other RPs, including some
of those described as activators of p53, can by itself disrupt ribo-
some biogenesis and elicit a p53 response, yet this is not the case
for RPL11 and RPL5 [78,79]. Although partial depletion of either
RPL5 or RPL11 results in growth arrest, this is rather due to a global
reduction in protein synthesis and not because a p53 activation
program has been executed [78]. The critical role of both RPL5
and RPL11 in p53 activation following ribosome biogenesis impair-
ment accentuates the observation that, upon exposure of cells to
various ribosome biogenesis stressors, endogenous RPL5 and
RPL11 are unique among several other RPs examined in being able
to accumulate in the non-ribosomal fraction, where they speciﬁ-
cally bind Mdm2 [80]. Furthermore, the signiﬁcance of RPL5 and
RPL11 in p53 activation upon inhibition of ribosome biogenesis
or upon c-MYC overexpression is convincingly supported by the
analysis of the Mdm2C305F mouse model [75].
How exactly do the different RPs mediate the p53 stress
response? Following translation, RPs are shuttled from theRPL
2
RPS
RPL
RPL5
RPL11
RPL11 RPL5
RPL11
L11
40S
RPS
60S
RPL
40S
RPS
60S
RPL
40S
RPS
60S
RPL
5’TOP
5’TOP
5’TOP
p53
p53
Enhanced RPL11 translation
Proteasomal degradation
B
fusion model: following a stress signal, RPs are free to diffuse from the nucleoplasm,
ted (see also Table 1). (B) Translational source of p53 activating RPs. Upper panel:
manner is enhanced, causing RPL11 to accumulate and activate p53. Lower panel:
ed into the nucleus, where they bind Mdm2 and activate p53. Other RPs fail to enter
SL1
UBF
polI
rRNA
p53
c-MYC
ARF
ERK
p21
RP
Rb
IPO7
XPO1
mTOR
PTEN
TSC2
Fig. 3. p53 inhibits ribosome biogenesis via direct and indirect mechanisms. See
text for further details.
L. Golomb et al. / FEBS Letters 588 (2014) 2571–2579 2575cytoplasm into the nucleus in an energy-dependent manner,
assisted by the beta-karyopherin family members [81,82]. RPs
are basic proteins, which aggregate quickly in the cytoplasm if
not bound and transported by the import machinery [83]. After
nuclear import, RPs accumulate in the nucleolus, where they are
assembled together with rRNA into ribosomal subunits (Fig. 1A).
There has been considerable controversy regarding the source of
p53-activating RPs upon ribosome biogenesis stress. It was initially
perceived that perturbed ribosome biogenesis, resulting in nucleo-
lar disruption, impel the diffusion of a number of RPs from the
nucleolus into the nucleoplasm, where they are free to bind
Mdm2 and activate p53 (Fig. 2A) [67]. Yet, new evidence is now
challenging this dogma, raising alternative assumptions regarding
the source and type of the RPs that signal to p53 activation [18,80].
Although some impairments of ribosome biogenesis do not
cause an obvious nucleolar damage, they still can activate p53 in
an RPL11/Mdm2-dependent manner. For example, knockdown of
RPS6 interrupts the biogenesis of the 40S small ribosomal subunit
and activates p53, yet without evident disruption of nucleolar
integrity [22]. In that case, mRNAs containing 50TOP are preferen-
tially translated, including that of RPL11 and possibly other RPs,
resulting in accumulation of excessive free RPL11 protein and sub-
sequent p53 activation (Fig. 2B) [22].
The most recent model also implicates protein synthesis as the
source of p53-activating RPs upon impairment of ribosome biogen-
esis. It proposes that under such conditions all RPs are normally
synthesized (Fig. 2B) [80]. However, while other RPs are quickly
dismissed via proteasome-mediated degradation, RPL5 and RPL11
are protected from degradation and continue to be imported into
the nucleolus where they bind Mdm2 and activate p53 (Fig. 2B)
[80], implying that RPL11 and RPL5, each independently yet mutu-
ally, are essential factors in mediating the ribosome biogenesis
stress signal to p53. We have recently demonstrated that depletion
of a single nuclear import factor, Importin 7 (IPO7), triggers a p53
response that is dependent on both RPL5 and RPL11 [30]. These
two RPs are likely imported via several parallel importins [5,81],
and are thus not dependent on a single import factor. Hence, while
the import of other RPs such as RPL4 is impaired upon IPO7 deple-
tion, leading to ribosome biogenesis stress, sustained import of
RPL5 and RPL11 by other import factors allows p53 activation
under these conditions (Fig. 1B).
In addition to RPL5 and RPL11, recent reports highlight also the
importance of 5S rRNA, as part of the 5S RNP complex, as a neces-
sary element in ribosome biogenesis stress signaling to p53. Specif-
ically, depleting 5S rRNA with the aid of siRNA targeted against the
PolIII transcription factor TIFIIIA prevents ribosomal biogenesis
stress-dependent activation of p53 [84,85]. In addition, siRNA tar-
geting 5S rRNA directly was found to lower the levels of Mdmx, an
Mdm2-related protein required for maximizing the E3 ligase activ-
ity of Mdm2, thereby enhancing p53 activity [86]. Thus, it seems
that under conditions of ribosome biogenesis stress, newly synthe-
sized RPL5/RPL11/5S rRNA complex is redirected from ribosome
biogenesis to the Mdm2/p53 module (Fig. 2B).
Signaling through the RPL11/RPL5/5S complex is also supported
by additional factors such as RPL37, which is degraded following
DNA damage, inducing RPL11 binding to Mdm2 [87]. Non-ribo-
somal proteins also assist with this process, as exempliﬁed by
the nucleolar protein PICT1, which regulates RPL11 release from
the nucleolus upon ribosomal stress [88], and the splicing factor
SRSF1, which cooperates with RPL5 in p53 activation and driving
of normal ﬁbroblasts into senescence [89].
RPs can also convey the stress message to p53 via alternative
mechanisms. Of note, RPL11 was found to enhance p53 transcrip-
tional activity through its ability to bind p53 target genes and aug-
ment recruitment of the p300/CBP acetyltransferases and p53
acetylation [90]. These authors also reported that the Neddylationof RPL11 is crucial for its ability to alleviate Mdm2-dependent
repression of p53 transcriptional activity. Another unique example
is provided by RPL26: although, like many other RPs, RPL26 can
bind Mdm2 and activate p53 in the canonical manner [91], this
RP also binds and enhances the translation of p53 mRNA [92,93].
Under basal conditions RPL26 is bound to Mdm2, which prevents
it from enhancing p53 mRNA translation. Furthermore, RPL26 is
a direct target for Mdm2-mediated polyubiquitylation and degra-
dation. However, upon genotoxic stress the inhibitory effect of
Mdm2 over RPL26 is attenuated, enabling rapid p53 translation
[92]. Strikingly, TGF-b1 can dampen the cellular stress response
by hindering the ability of RPL26 to enhance p53 mRNA translation
[94].
Conversely, some RPs can mediate tumor suppression indepen-
dently of p53. For instance, both RPL11 and RPS14 were reported to
bind the N-terminal MBII domain of c-MYC and avert the binding
of the c-MYC coactivator TRRAP [95–97], thereby inhibiting
c-MYC-mediated transactivation of target genes. Additionally,
RPL11 and RPL5 bind the 30UTR of c-MYC mRNA, leading to its
microRNA/RISC-mediated degradation [98,99]. Moreover, RPS3
was found to have a dual activity of both enhancing DNA damage
repair, thereby contributing to genome stability [100], and mediat-
ing apoptosis [101,102].
5. The p53-ARF axis constrains ribosome biogenesis
In light of the oncogenic potential of the protein synthesis
apparatus, it is perhaps not surprising that in addition to being
activated in response to deregulated ribosome biogenesis, p53
can also curb ribosome biogenesis, either through its activity as a
transcription factor or through direct binding to different elements
in this pathway (Fig. 3). Thus, p53 can quench the activity of RNA
PolI and RNA PolIII, in the latter case through direct binding to
TFIIIB [103,104]. In the case of PolI, p53 was shown to hinder the
assembly of the RNA PolI initiation complex via its interaction with
SL1, with resultant attenuation of the formation of the SL1/UBF
complex [105]. In addition, p53 constrains rRNA transcription
indirectly through several mechanisms. For example the CDK
inhibitor p21, product of one of p53’s main transcriptional target
genes, activates the retinoblastoma tumor suppressor protein
(pRB), a potent inhibitor of rRNA transcription [106,107]. Addition-
ally, p53 can impede ribosome biogenesis indirectly by
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mTOR [110,111], attenuating ribosome biogenesis at multiple lev-
els (Fig. 3).
One intriguing possibility is that p53 may inﬂuence the trafﬁck-
ing of RPs and ribosomal subunits. Induction of DNA damage alters
the subcellular accumulation of many RPs in p53-proﬁcient but not
p53-deﬁcient cells [112].Strikingly, p53 represses the transcription
of the IPO7 gene as well as that of Exportin 1 (XPO1) [30,113], better
known as CRM1 – the main protein responsible for the nuclear
export of assembled ribosome subunits [114]. Remarkably, the
same genes are upregulated by c-MYC. Thus activated p53 may
dampen the nuclear trafﬁc of ribosomal proteins and ribosomal
subunits, stalling ribosome biogenesis in response to genotoxic
stress and coordinating cell cycle arrest with the attenuation of
protein synthesis. As p53 can also inﬂuence the overall levels of
RPs via multiple direct and indirect mechanisms (Fig. 3), further
experimental evidence will be required to establish a direct role
for p53 in regulating the shuttling of RPs and ribosome subunits.
As discussed above, ARF is a major component of the p53 path-
way. Remarkably, ARF also possesses a p53-independent ability to
constrain ribosome biogenesis [115] (Fig. 3). ARF can obstruct rRNA
processing [116,117], as well as interfere with rRNA transcription
through direct binding to rDNA gene promoter regions and via
interference with UBF phosphorylation [118,119]. Additionally,
ARF can affect rRNA transcription via sequestration of TTF-I outside
of the nucleolus [120] and inhibition of Mdm2-dependent ubiquiti-
nation of TTF-I [121]. Consistent with these ﬁndings, recent reports
suggest that ARF can trigger the RPL5/RPL11/Mdm2/p53 check-
point via suppression of several steps of ribosome biogenesis and
physically and functionally interacting with the p53-activating
RPL11 under these conditions [85,122]. Together, these ﬁndings
underscore the complexity of ribosome biogenesis regulation by
the p53-ARF axis, suggesting that this tumor suppressive pathway
constitutes an important barrier against tumorigenesis.
6. The ribosome biogenesis machinery as a putative cancer
therapy target
The understanding that excessive ribosome biogenesis pro-
motes tumorigenesis but this machinery also serves as a funda-
mental component of the stress signaling apparatus, led several
groups to try and develop anti-cancer treatments exploiting these
two features. Although in about 50% of all human cancers p53 is
inactivated via mutations or deletions, the remainder half retain
wild type (WT) p53, apparently incapacitated as a tumor suppres-
sor. As discussed above, p53 activation can be triggered by sup-
pression of ribosome biogenesis. This notion has led to the idea
of treating tumors harboring WT p53 with a low dose of ActD,
thereby inhibiting RNA PolI activity while minimizing non-speciﬁc
adverse effects [123]. Other chemotherapeutic agents like 5-FU,
cisplatin, temsirolimus, mitomycin C and irinotecan/topotecan,
were also shown to exert some of their anti-cancer effects via
obstructing RNA PolI activity [10]; however, all of them also induce
genomic damage and other adverse effects. Recently, high speciﬁc-
ity RNA PolI inhibitors were developed: the small molecule
CX-5461 speciﬁcally blocks the binding of SL1 to the promoter of
rDNA genes, thus preventing rRNA transcription [124]. Strikingly,
while CX-5461 induces a very potent p53 response in blood malig-
nancies [125], it can also restrain the growth of human solid
tumors independently of p53 [124]. Another small molecule,
BMH-21, was recently reported to target PolI activity through its
ability to promote the proteasomal degradation of RPA194, the
large catalytic subunit of PolI holocomplex [126]. Although
BMH-21 intercalates into DNA with high afﬁnity to GC-rich
regions, it does not elicit a DNA damage response [127] and itsability to activate p53 is probably mediated by ribosome biogene-
sis stress. This promising agent was shown to effectively impede
the growth of different cancer cells, both in vitro and in vivo
[126]. Both cases serve as a proof of concept, demonstrating how
speciﬁc targeting of RNA PolI can strike tumors at two key points
in parallel, suppressing a core cellular function required for the fast
proliferation of cancer cells while activating an anti-tumoral p53
response.
7. Conclusions
Our growing understanding of the biology of ribosome biogen-
esis unexpectedly opened up a new and exciting ﬁeld in cancer
biology. As evidence accumulates, we can now appreciate the role
of p53 in both sensing the ﬁdelity of ribosome biogenesis as well as
constraining it, thereby coordinating cell growth with cell cycle
progression and mediating an additional layer of protection against
cancer.
Although it has been known for many years that the ribosome
biogenesis machinery is dysregulated in cancer, we now under-
stand that inherited and acquired abnormalities in ribosome func-
tion can lead to tumorigenesis and thus it can be speculated that
activation of a p53-dependent checkpoint response might prevent
expansion of such potentially hazardous cells. Although there are
some indications in support of this idea, deﬁnitive evidence has
not yet been provided. As patients of DBA and other ribosomopa-
thies are predisposed to various malignancies, it is imperative to
understand whether chronic p53 activation in ribosomopathy-
derived cells is a driving pressure for p53 inactivation by muta-
tions, deletions or epigenetic mechanisms, enabling neoplastic
growth. Additionally, p53-downstream signaling pathways that
mediate its effect of other pathological phenotypes in ribosomop-
athies need to be uncovered.
Many open questions still linger regarding the mechanisms of
p53 activation following ribosomal stress. The spatial and temporal
interaction of the p53/Mdm2 module with RPs is still largely unre-
solved, including the ability of the nucleolus to regulate p53 local-
ization, shuttling and degradation. Moreover, we do not fully
understand why RPL5 and RPL11 are so unique in activating p53,
when so many other RPs are capable of binding Mdm2.
Transferring the current knowledge in this ﬁeld from mostly
in vitro models to in vivo mouse models will constitute the next
phase in utilizing the p53-RP connection for better understanding
of cancer biology, hopefully harnessing this knowledge towards
the introduction of new and improved cancer treatments.
Acknowledgements
We apologize to all the many authors whose important relevant
contributions could not be included owing to space limitations.
Work in the authors’ laboratory is partially supported by the Dr.
Miriam and Sheldon G. Adelson Medical Research Foundation, a
Center of Excellence grant (1779/11) from the Israel Science
Foundation, a Center of Excellence grant from the Flight Attendant
Medical Research Institute (FAMRI), and EC FP7 funding (INFLA-
CARE, agreement 223151).
References
[1] Hanahan, D. and Weinberg, R.A. (2011) Hallmarks of cancer: the next
generation. Cell 144, 646–674.
[2] Dez, C. and Tollervey, D. (2004) Ribosome synthesis meets the cell cycle. Curr.
Opin. Microbiol. 7, 631–637.
[3] van Riggelen, J., Yetil, A. and Felsher, D.W. (2010) MYC as a regulator of
ribosome biogenesis and protein synthesis. Nat. Rev. Cancer 10, 301–309.
[4] Warner, J.R. (1999) The economics of ribosome biosynthesis in yeast. Trends
Biochem. Sci. 24, 437–440.
L. Golomb et al. / FEBS Letters 588 (2014) 2571–2579 2577[5] Kressler, D., Bange, G., Ogawa, Y., Stjepanovic, G., Bradatsch, B., Pratte, D.,
Amlacher, S., Strauss, D., Yoneda, Y., Katahira, J., Sinning, I. and Hurt, E. (2012)
Synchronizing nuclear import of ribosomal proteins with ribosome assembly.
Science 338, 666–671.
[6] Zemp, I. and Kutay, U. (2007) Nuclear export and cytoplasmic maturation of
ribosomal subunits. FEBS Lett. 581, 2783–2793.
[7] Leary, D.J. and Huang, S. (2001) Regulation of ribosome biogenesis within the
nucleolus. FEBS Lett. 509, 145–150.
[8] Montanaro, L., Trere, D. and Derenzini, M. (2012) Changes in ribosome
biogenesis may induce cancer by down-regulating the cell tumor suppressor
potential. Biochim. Biophys. Acta 1825, 101–110.
[9] Ruggero, D. and Pandolﬁ, P.P. (2003) Does the ribosome translate cancer? Nat.
Rev. Cancer 3, 179–192.
[10] Hannan, K.M., Sanij, E., Rothblum, L.I., Hannan, R.D. and Pearson, R.B. (2013)
Dysregulation of RNA polymerase I transcription during disease. Biochim.
Biophys. Acta 1829, 342–360.
[11] Drygin, D., Rice, W.G. and Grummt, I. (2010) The RNA polymerase I
transcription machinery: an emerging target for the treatment of cancer.
Annu. Rev. Pharmacol. Toxicol. 50, 131–156.
[12] Pogue-Geile, K., Geiser, J.R., Shu, M., Miller, C., Wool, I.G., Meisler, A.I. and
Pipas, J.M. (1991) Ribosomal protein genes are overexpressed in colorectal
cancer: isolation of a cDNA clone encoding the human S3 ribosomal protein.
Mol. Cell. Biol. 11, 3842–3849.
[13] Lai, M.D. and Xu, J. (2007) Ribosomal proteins and colorectal cancer. Curr.
Genomics 8, 43–49.
[14] Wang, Q., Yang, C., Zhou, J., Wang, X., Wu, M. and Liu, Z. (2001) Cloning and
characterization of full-length human ribosomal protein L15 cDNA which
was overexpressed in esophageal cancer. Gene 263, 205–209.
[15] Kim, J.H., You, K.R., Kim, I.H., Cho, B.H., Kim, C.Y. and Kim, D.G. (2004) Over-
expression of the ribosomal protein L36a gene is associated with cellular
proliferation in hepatocellular carcinoma. Hepatology 39, 129–138.
[16] Warner, J.R. and McIntosh, K.B. (2009) How common are extraribosomal
functions of ribosomal proteins? Mol. Cell 34, 3–11.
[17] Boulon, S., Westman, B.J., Hutten, S., Boisvert, F.M. and Lamond, A.I. (2010)
The nucleolus under stress. Mol. Cell 40, 216–227.
[18] Bursac, S., Donati, G., Brdovcak, M.C. and Volarevic, S. (2013) Activation of the
tumor suppressor p53 upon impairment of ribosome biogenesis. Biochim.
Biophys. Acta 1842, 817–830.
[19] Grummt, I. (2013) The nucleolus-guardian of cellular homeostasis and
genome integrity. Chromosoma 122, 487–497.
[20] Burger, K., Muhl, B., Harasim, T., Rohrmoser, M., Malamoussi, A., Orban, M.,
Kellner, M., Gruber-Eber, A., Kremmer, E., Holzel, M. and Eick, D. (2010)
Chemotherapeutic drugs inhibit ribosome biogenesis at various levels. J. Biol.
Chem. 285, 12416–12425.
[21] Shav-Tal, Y., Blechman, J., Darzacq, X., Montagna, C., Dye, B.T., Patton, J.G.,
Singer, R.H. and Zipori, D. (2005) Dynamic sorting of nuclear components into
distinct nucleolar caps during transcriptional inhibition. Mol. Biol. Cell 16,
2395–2413.
[22] Fumagalli, S., Di Cara, A., Neb-Gulati, A., Natt, F., Schwemberger, S., Hall, J.,
Babcock, G.F., Bernardi, R., Pandolﬁ, P.P. and Thomas, G. (2009) Absence of
nucleolar disruption after impairment of 40S ribosome biogenesis reveals an
rpL11-translation-dependent mechanism of p53 induction. Nat. Cell Biol. 11,
501–508.
[23] Rubbi, C.P. and Milner, J. (2003) Disruption of the nucleolus mediates
stabilization of p53 in response to DNA damage and other stresses. EMBO J.
22, 6068–6077.
[24] Bhat, K.P., Itahana, K., Jin, A. and Zhang, Y. (2004) Essential role of ribosomal
protein L11 in mediating growth inhibition-induced p53 activation. EMBO J.
23, 2402–2412.
[25] Lane, D.P. (1992) Cancer. p53, guardian of the genome. Nature 358, 15–16.
[26] Meek, D.W. (2009) Tumour suppression by p53: a role for the DNA damage
response? Nat. Rev. Cancer 9, 714–723.
[27] Pestov, D.G., Strezoska, Z. and Lau, L.F. (2001) Evidence of p53-dependent
cross-talk between ribosome biogenesis and the cell cycle: effects
of nucleolar protein Bop1 on G(1)/S transition. Mol. Cell. Biol. 21, 4246–
4255.
[28] Yuan, X., Zhou, Y., Casanova, E., Chai, M., Kiss, E., Grone, H.J., Schutz, G. and
Grummt, I. (2005) Genetic inactivation of the transcription factor TIF-IA leads
to nucleolar disruption, cell cycle arrest, and p53-mediated apoptosis. Mol.
Cell 19, 77–87.
[29] Donati, G., Bertoni, S., Brighenti, E., Vici, M., Trere, D., Volarevic, S.,
Montanaro, L. and Derenzini, M. (2011) The balance between rRNA and
ribosomal protein synthesis up- and downregulates the tumour suppressor
p53 in mammalian cells. Oncogene 30, 3274–3288.
[30] Golomb, L., Bublik, D.R., Wilder, S., Nevo, R., Kiss, V., Grabusic, K., Volarevic, S.
and Oren, M. (2012) Importin 7 and exportin 1 link c-Myc and p53 to
regulation of ribosomal biogenesis. Mol. Cell 45, 222–232.
[31] Sulic, S., Panic, L., Barkic, M., Mercep, M., Uzelac, M. and Volarevic, S. (2005)
Inactivation of S6 ribosomal protein gene in T lymphocytes activates a p53-
dependent checkpoint response. Genes Dev. 19, 3070–3082.
[32] Panic, L., Tamarut, S., Sticker-Jantscheff, M., Barkic, M., Solter, D., Uzelac, M.,
Grabusic, K. and Volarevic, S. (2006) Ribosomal protein S6 gene
haploinsufﬁciency is associated with activation of a p53-dependent
checkpoint during gastrulation. Mol. Cell. Biol. 26, 8880–8891.
[33] Narla, A., Hurst, S.N. and Ebert, B.L. (2011) Ribosome defects in disorders of
erythropoiesis. Int. J. Hematol. 93, 144–149.[34] Lipton, J.M. (2006) Diamond blackfan anemia: new paradigms for a ‘‘not so
pure’’ inherited red cell aplasia. Semin. Hematol. 43, 167–177.
[35] Vlachos, A., Rosenberg, P.S., Atsidaftos, E., Alter, B.P. and Lipton, J.M. (2012)
Incidence of neoplasia in Diamond Blackfan anemia: a report from the
Diamond Blackfan Anemia Registry. Blood 119, 3815–3819.
[36] Farrar, J.E., Vlachos, A., Atsidaftos, E., Carlson-Donohoe, H., Markello, T.C.,
Arceci, R.J., Ellis, S.R., Lipton, J.M. and Bodine, D.M. (2011) Ribosomal protein
gene deletions in Diamond–Blackfan anemia. Blood 118, 6943–6951.
[37] Ebert, B.L., Pretz, J., Bosco, J., Chang, C.Y., Tamayo, P., Galili, N., Raza, A., Root,
D.E., Attar, E., Ellis, S.R. and Golub, T.R. (2008) Identiﬁcation of RPS14 as a 5q-
syndrome gene by RNA interference screen. Nature 451, 335–339.
[38] Bolze, A., Mahlaoui, N., Byun, M., Turner, B., Trede, N., Ellis, S.R., Abhyankar,
A., Itan, Y., Patin, E., Brebner, S., Sackstein, P., Puel, A., Picard, C., Abel, L.,
Quintana-Murci, L., Faust, S.N., Williams, A.P., Baretto, R., Duddridge, M., Kini,
U., Pollard, A.J., Gaud, C., Frange, P., Orbach, D., Emile, J.F., Stephan, J.L.,
Sorensen, R., Plebani, A., Hammarstrom, L., Conley, M.E., Selleri, L. and
Casanova, J.L. (2013) Ribosomal protein SA haploinsufﬁciency in humans
with isolated congenital asplenia. Science 340, 976–978.
[39] Narla, A. and Ebert, B.L. (2010) Ribosomopathies: human disorders of
ribosome dysfunction. Blood 115, 3196–3205.
[40] Danilova, N., Sakamoto, K.M. and Lin, S. (2008) Ribosomal protein S19
deﬁciency in zebraﬁsh leads to developmental abnormalities and defective
erythropoiesis through activation of p53 protein family. Blood 112, 5228–
5237.
[41] McGowan, K.A., Li, J.Z., Park, C.Y., Beaudry, V., Tabor, H.K., Sabnis, A.J., Zhang,
W., Fuchs, H., de Angelis, M.H., Myers, R.M., Attardi, L.D. and Barsh, G.S.
(2008) Ribosomal mutations cause p53-mediated dark skin and pleiotropic
effects. Nat. Genet. 40, 963–970.
[42] Dutt, S., Narla, A., Lin, K., Mullally, A., Abayasekara, N., Megerdichian, C.,
Wilson, F.H., Currie, T., Khanna-Gupta, A., Berliner, N., Kutok, J.L. and Ebert,
B.L. (2011) Haploinsufﬁciency for ribosomal protein genes causes selective
activation of p53 in human erythroid progenitor cells. Blood 117, 2567–2576.
[43] Wei, S., Chen, X., McGraw, K., Zhang, L., Komrokji, R., Clark, J., Caceres, G.,
Billingsley, D., Sokol, L., Lancet, J., Fortenbery, N., Zhou, J., Eksioglu, E.A.,
Sallman, D., Wang, H., Epling-Burnette, P.K., Djeu, J., Sekeres, M., Maciejewski,
J.P. and List, A. (2013) Lenalidomide promotes p53 degradation by inhibiting
MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome
5q deletion. Oncogene 32, 1110–1120.
[44] Michael, D. and Oren, M. (2003) The p53-Mdm2 module and the ubiquitin
system. Semin. Cancer Biol. 13, 49–58.
[45] Haupt, Y., Maya, R., Kazaz, A. and Oren, M. (1997) Mdm2 promotes the rapid
degradation of p53. Nature 387, 296–299.
[46] Honda, R., Tanaka, H. and Yasuda, H. (1997) Oncoprotein MDM2 is a ubiquitin
ligase E3 for tumor suppressor p53. FEBS Lett. 420, 25–27.
[47] Freedman, D.A. and Levine, A.J. (1998) Nuclear export is required for
degradation of endogenous p53 by MDM2 and human papillomavirus E6.
Mol. Cell. Biol. 18, 7288–7293.
[48] Shirangi, T.R., Zaika, A. and Moll, U.M. (2002) Nuclear degradation of p53
occurs during down-regulation of the p53 response after DNA damage. FASEB
J. 16, 420–422.
[49] Xirodimas, D.P., Stephen, C.W. and Lane, D.P. (2001) Cocompartmentalization
of p53 and Mdm2 is a major determinant for Mdm2-mediated degradation of
p53. Exp. Cell Res. 270, 66–77.
[50] Tao, T., Shi, H., Guan, Y., Huang, D., Chen, Y., Lane, D.P., Chen, J. and Peng, J.
(2013) Def deﬁnes a conserved nucleolar pathway that leads p53 to
proteasome-independent degradation. Cell Res. 23, 620–634.
[51] Ashcroft, M., Kubbutat, M.H. and Vousden, K.H. (1999) Regulation of p53
function and stability by phosphorylation. Mol. Cell. Biol. 19, 1751–1758.
[52] Meek, D.W. (1998) Multisite phosphorylation and the integration of stress
signals at p53. Cell. Signal. 10, 159–166.
[53] Gu, W. and Roeder, R.G. (1997) Activation of p53 sequence-speciﬁc DNA
binding by acetylation of the p53 C-terminal domain. Cell 90, 595–606.
[54] Brooks, C.L. and Gu, W. (2011) The impact of acetylation and deacetylation on
the p53 pathway. Protein Cell 2, 456–462.
[55] Maya, R., Balass, M., Kim, S.T., Shkedy, D., Leal, J.F., Shifman, O., Moas, M.,
Buschmann, T., Ronai, Z., Shiloh, Y., Kastan, M.B., Katzir, E. and Oren, M.
(2001) ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53
activation by DNA damage. Genes Dev. 15, 1067–1077.
[56] Pereg, Y., Shkedy, D., de Graaf, P., Meulmeester, E., Edelson-Averbukh, M.,
Salek, M., Biton, S., Teunisse, A.F., Lehmann, W.D., Jochemsen, A.G. and Shiloh,
Y. (2005) Phosphorylation of Hdmx mediates its Hdm2- and ATM-dependent
degradation in response to DNA damage. Proc. Natl. Acad. Sci. USA 102,
5056–5061.
[57] Weber, J.D., Taylor, L.J., Roussel, M.F., Sherr, C.J. and Bar-Sagi, D. (1999)
Nucleolar Arf sequesters Mdm2 and activates p53. Nat. Cell Biol. 1, 20–26.
[58] Zindy, F., Eischen, C.M., Randle, D.H., Kamijo, T., Cleveland, J.L., Sherr, C.J. and
Roussel, M.F. (1998) Myc signaling via the ARF tumor suppressor regulates
p53-dependent apoptosis and immortalization. Genes Dev. 12, 2424–2433.
[59] Kamijo, T., Weber, J.D., Zambetti, G., Zindy, F., Roussel, M.F. and Sherr, C.J.
(1998) Functional and physical interactions of the ARF tumor suppressor
with p53 and Mdm2. Proc. Natl. Acad. Sci. USA 95, 8292–8297.
[60] Zhang, Y., Xiong, Y. and Yarbrough, W.G. (1998) ARF promotes MDM2
degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the
Rb and p53 tumor suppression pathways. Cell 92, 725–734.
[61] Fontoura, B.M., Sorokina, E.A., David, E. and Carroll, R.B. (1992) P53 is
covalently linked to 5.8S rRNA. Mol. Cell. Biol. 12, 5145–5151.
2578 L. Golomb et al. / FEBS Letters 588 (2014) 2571–2579[62] Samad, A. and Carroll, R.B. (1991) The tumor suppressor p53 is bound to RNA
by a stable covalent linkage. Mol. Cell. Biol. 11, 1598–1606.
[63] Marechal, V., Elenbaas, B., Piette, J., Nicolas, J.C. and Levine, A.J. (1994) The
ribosomal L5 protein is associated with mdm-2 and mdm-2-p53 complexes.
Mol. Cell. Biol. 14, 7414–7420.
[64] Zhang, Y., Wolf, G.W., Bhat, K., Jin, A., Allio, T., Burkhart, W.A. and Xiong, Y.
(2003) Ribosomal protein L11 negatively regulates oncoprotein MDM2 and
mediates a p53-dependent ribosomal-stress checkpoint pathway. Mol. Cell.
Biol. 23, 8902–8912.
[65] Dai, M.S. and Lu, H. (2004) Inhibition of MDM2-mediated p53 ubiquitination
and degradation by ribosomal protein L5. J. Biol. Chem. 279, 44475–44482.
[66] Jin, A., Itahana, K., O’Keefe, K. and Zhang, Y. (2004) Inhibition of HDM2 and
activation of p53 by ribosomal protein L23. Mol. Cell. Biol. 24, 7669–7680.
[67] Zhang, Y. and Lu, H. (2009) Signaling to p53: ribosomal proteins ﬁnd their
way. Cancer Cell 16, 369–377.
[68] Lindstrom, M.S., Jin, A., Deisenroth, C., White Wolf, G. and Zhang, Y. (2007)
Cancer-associated mutations in the MDM2 zinc ﬁnger domain disrupt
ribosomal protein interaction and attenuate MDM2-induced p53
degradation. Mol. Cell. Biol. 27, 1056–1068.
[69] Qin, X.Q., Livingston, D.M., Kaelin Jr., W.G. and Adams, P.D. (1994)
Deregulated transcription factor E2F-1 expression leads to S-phase entry
and p53-mediated apoptosis. Proc. Natl. Acad. Sci. USA 91, 10918–10922.
[70] Serrano, M., Lin, A.W., McCurrach, M.E., Beach, D. and Lowe, S.W. (1997)
Oncogenic ras provokes premature cell senescence associated with
accumulation of p53 and p16INK4a. Cell 88, 593–602.
[71] Di Micco, R., Fumagalli, M., Cicalese, A., Piccinin, S., Gasparini, P., Luise, C.,
Schurra, C., Garre, M., Nuciforo, P.G., Bensimon, A., Maestro, R., Pelicci, P.G.
and d’Adda di Fagagna, F. (2006) Oncogene-induced senescence is a DNA
damage response triggered by DNA hyper-replication. Nature 444, 638–642.
[72] Bartkova, J., Rezaei, N., Liontos, M., Karakaidos, P., Kletsas, D., Issaeva, N.,
Vassiliou, L.V., Kolettas, E., Niforou, K., Zoumpourlis, V.C., Takaoka, M.,
Nakagawa, H., Tort, F., Fugger, K., Johansson, F., Sehested, M., Andersen, C.L.,
Dyrskjot, L., Orntoft, T., Lukas, J., Kittas, C., Helleday, T., Halazonetis, T.D.,
Bartek, J. and Gorgoulis, V.G. (2006) Oncogene-induced senescence is part of
the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 444,
633–637.
[73] Lin, A.W. and Lowe, S.W. (2001) Oncogenic ras activates the ARF-p53
pathway to suppress epithelial cell transformation. Proc. Natl. Acad. Sci. USA
98, 5025–5030.
[74] Aylon, Y., Yabuta, N., Besserglick, H., Buganim, Y., Rotter, V., Nojima, H. and
Oren, M. (2009) Silencing of the Lats2 tumor suppressor overrides a p53-
dependent oncogenic stress checkpoint and enables mutant H-Ras-driven
cell transformation. Oncogene 28, 4469–4479.
[75] Macias, E., Jin, A., Deisenroth, C., Bhat, K., Mao, H., Lindstrom, M.S. and Zhang,
Y. (2010) An ARF-independent c-MYC-activated tumor suppression pathway
mediated by ribosomal protein-Mdm2 Interaction. Cancer Cell 18, 231–243.
[76] Pan, W., Issaq, S. and Zhang, Y. (2011) The in vivo role of the RP-Mdm2-p53
pathway in signaling oncogenic stress induced by pRb inactivation and Ras
overexpression. PLoS One 6, e21625.
[77] Brookes, S., Rowe, J., Ruas, M., Llanos, S., Clark, P.A., Lomax, M., James, M.C.,
Vatcheva, R., Bates, S., Vousden, K.H., Parry, D., Gruis, N., Smit, N., Bergman,
W. and Peters, G. (2002) INK4a-deﬁcient human diploid ﬁbroblasts are
resistant to RAS-induced senescence. EMBO J. 21, 2936–2945.
[78] Teng, T., Mercer, C.A., Hexley, P., Thomas, G. and Fumagalli, S. (2013) Loss of
tumor suppressor RPL5/RPL11 does not induce cell cycle arrest but impedes
proliferation due to reduced ribosome content and translation capacity. Mol.
Cell. Biol. 33, 4660–4671.
[79] Fumagalli, S., Ivanenkov, V.V., Teng, T. and Thomas, G. (2012) Suprainduction
of p53 by disruption of 40S and 60S ribosome biogenesis leads to the
activation of a novel G2/M checkpoint. Genes Dev. 26, 1028–1040.
[80] Bursac, S., Brdovcak, M.C., Pfannkuchen, M., Orsolic, I., Golomb, L., Zhu, Y.,
Katz, C., Daftuar, L., Grabusic, K., Vukelic, I., Filic, V., Oren, M., Prives, C. and
Volarevic, S. (2012) Mutual protection of ribosomal proteins L5 and L11 from
degradation is essential for p53 activation upon ribosomal biogenesis stress.
Proc. Natl. Acad. Sci. USA 109, 20467–20472.
[81] Jakel, S. and Gorlich, D. (1998) Importin beta, transportin, RanBP5 and
RanBP7 mediate nuclear import of ribosomal proteins in mammalian cells.
EMBO J. 17, 4491–4502.
[82] Rout, M.P., Blobel, G. and Aitchison, J.D. (1997) A distinct nuclear import
pathway used by ribosomal proteins. Cell 89, 715–725.
[83] Jakel, S., Mingot, J.M., Schwarzmaier, P., Hartmann, E. and Gorlich, D. (2002)
Importins fulﬁl a dual function as nuclear import receptors and cytoplasmic
chaperones for exposed basic domains. EMBO J. 21, 377–386.
[84] Donati, G., Peddigari, S., Mercer, C.A. and Thomas, G. (2013) 5S ribosomal RNA
is an essential component of a nascent ribosomal precursor complex that
regulates the Hdm2-p53 checkpoint. Cell Rep. 4, 87–98.
[85] Sloan, K.E., Bohnsack, M.T. and Watkins, N.J. (2013) The 5S RNP couples p53
homeostasis to ribosome biogenesis and nucleolar stress. Cell Rep. 5, 237–
247.
[86] Li, M. and Gu, W. (2011) A critical role for non-coding 5S rRNA in regulating
Mdmx stability. Mol. Cell 43, 1023–1032.
[87] Llanos, S. and Serrano, M. (2010) Depletion of ribosomal protein L37 occurs in
response to DNA damage and activates p53 through the L11/MDM2 pathway.
Cell Cycle 9, 4005–4012.
[88] Sasaki, M., Kawahara, K., Nishio, M., Mimori, K., Kogo, R., Hamada, K., Itoh, B.,
Wang, J., Komatsu, Y., Yang, Y.R., Hikasa, H., Horie, Y., Yamashita, T., Kamijo,T., Zhang, Y., Zhu, Y., Prives, C., Nakano, T., Mak, T.W., Sasaki, T., Maehama, T.,
Mori, M. and Suzuki, A. (2011) Regulation of the MDM2-P53 pathway and
tumor growth by PICT1 via nucleolar RPL11. Nat. Med. 17, 944–951.
[89] Fregoso, O.I., Das, S., Akerman, M. and Krainer, A.R. (2013) Splicing-factor
oncoprotein SRSF1 stabilizes p53 via RPL5 and induces cellular senescence.
Mol. Cell 50, 56–66.
[90] Mahata, B., Sundqvist, A. and Xirodimas, D.P. (2012) Recruitment of RPL11 at
promoter sites of p53-regulated genes upon nucleolar stress through NEDD8
and in an Mdm2-dependent manner. Oncogene 31, 3060–3071.
[91] Zhang, Y., Wang, J., Yuan, Y., Zhang, W., Guan, W., Wu, Z., Jin, C., Chen, H.,
Zhang, L., Yang, X. and He, F. (2010) Negative regulation of HDM2 to
attenuate p53 degradation by ribosomal protein L26. Nucleic Acids Res. 38,
6544–6554.
[92] Oﬁr-Rosenfeld, Y., Boggs, K., Michael, D., Kastan, M.B. and Oren, M. (2008)
Mdm2 regulates p53 mRNA translation through inhibitory interactions with
ribosomal protein L26. Mol. Cell 32, 180–189.
[93] Takagi, M., Absalon, M.J., McLure, K.G. and Kastan, M.B. (2005) Regulation of
p53 translation and induction after DNA damage by ribosomal protein L26
and nucleolin. Cell 123, 49–63.
[94] Lopez-Diaz, F.J., Gascard, P., Balakrishnan, S.K., Zhao, J., Del Rincon, S.V.,
Spruck, C., Tlsty, T.D. and Emerson, B.M. (2013) Coordinate transcriptional
and translational repression of p53 by TGF-beta1 impairs the stress response.
Mol. Cell 50, 552–564.
[95] Dai, M.S., Arnold, H., Sun, X.X., Sears, R. and Lu, H. (2007) Inhibition of c-Myc
activity by ribosomal protein L11. EMBO J. 26, 3332–3345.
[96] Zhou, X., Hao, Q., Liao, J.M., Liao, P. and Lu, H. (2013) Ribosomal protein S14
negatively regulates c-Myc activity. J. Biol. Chem. 288, 21793–21801.
[97] Dai, M.S., Sun, X.X. and Lu, H. (2010) Ribosomal protein L11 associates with c-
Myc at 5 S rRNA and tRNA genes and regulates their expression. J. Biol. Chem.
285, 12587–12594.
[98] Challagundla, K.B., Sun, X.X., Zhang, X., DeVine, T., Zhang, Q., Sears, R.C. and
Dai, M.S. (2011) Ribosomal protein L11 recruits miR-24/miRISC to repress c-
Myc expression in response to ribosomal stress. Mol. Cell. Biol. 31, 4007–
4021.
[99] Liao, J.M., Zhou, X., Gatignol, A. and Lu, H. (2013) Ribosomal proteins L5 and
L11 co-operatively inactivate c-Myc via RNA-induced silencing complex.
Oncogene [Epub ahead of print].
[100] Hegde, V., Yadavilli, S., McLaughlin, L.D. and Deutsch, W.A. (2009) DNA repair
efﬁciency in transgenic mice over expressing ribosomal protein S3. Mutat.
Res. 666, 16–22.
[101] Jang, C.Y., Lee, J.Y. and Kim, J. (2004) RpS3, a DNA repair endonuclease and
ribosomal protein, is involved in apoptosis. FEBS Lett. 560, 81–85.
[102] Jang, C.Y., Kim, H.D. and Kim, J. (2012) Ribosomal protein S3 interacts with
TRADD to induce apoptosis through caspase dependent JNK activation.
Biochem. Biophys. Res. Commun. 421, 474–478.
[103] Chesnokov, I., Chu, W.M., Botchan, M.R. and Schmid, C.W. (1996) P53 inhibits
RNA polymerase III-directed transcription in a promoter-dependent manner.
Mol. Cell. Biol. 16, 7084–7088.
[104] Cairns, C.A. and White, R.J. (1998) P53 is a general repressor of RNA
polymerase III transcription. EMBO J. 17, 3112–3123.
[105] Zhai, W. and Comai, L. (2000) Repression of RNA polymerase I transcription
by the tumor suppressor p53. Mol. Cell. Biol. 20, 5930–5938.
[106] White, R.J., Trouche, D., Martin, K., Jackson, S.P. and Kouzarides, T. (1996)
Repression of RNA polymerase III transcription by the retinoblastoma
protein. Nature 382, 88–90.
[107] Voit, R., Schafer, K. and Grummt, I. (1997) Mechanism of repression of RNA
polymerase I transcription by the retinoblastoma protein. Mol. Cell. Biol. 17,
4230–4237.
[108] Levy, N., Yonish-Rouach, E., Oren, M. and Kimchi, A. (1993) Complementation
by wild-type p53 of interleukin-6 effects on M1 cells: induction of cell cycle
exit and cooperativity with c-myc suppression. Mol. Cell. Biol. 13, 7942–
7952.
[109] Ho, J.S., Ma, W., Mao, D.Y. and Benchimol, S. (2005) P53-Dependent
transcriptional repression of c-myc is required for G1 cell cycle arrest. Mol.
Cell. Biol. 25, 7423–7431.
[110] Feng, Z., Zhang, H., Levine, A.J. and Jin, S. (2005) The coordinate regulation of
the p53 and mTOR pathways in cells. Proc. Natl. Acad. Sci. USA 102, 8204–
8209.
[111] Stambolic, V., MacPherson, D., Sas, D., Lin, Y., Snow, B., Jang, Y., Benchimol, S.
and Mak, T.W. (2001) Regulation of PTEN transcription by p53. Mol. Cell 8,
317–325.
[112] Boisvert, F.M. and Lamond, A.I. (2010) P53-Dependent subcellular proteome
localization following DNA damage. Proteomics 10, 4087–4097.
[113] van der Watt, P.J. and Leaner, V.D. (2011) The nuclear exporter, Crm1, is
regulated by NFY and Sp1 in cancer cells and repressed by p53 in response to
DNA damage. Biochim. Biophys. Acta 1809, 316–326.
[114] Thomas, F. and Kutay, U. (2003) Biogenesis and nuclear export of ribosomal
subunits in higher eukaryotes depend on the CRM1 export pathway. J. Cell
Sci. 116, 2409–2419.
[115] Sherr, C.J. (2006) Divorcing ARF and p53: an unsettled case. Nat. Rev. Cancer
6, 663–673.
[116] Sugimoto, M., Kuo, M.L., Roussel, M.F. and Sherr, C.J. (2003) Nucleolar Arf
tumor suppressor inhibits ribosomal RNA processing. Mol. Cell 11, 415–424.
[117] Itahana, K., Bhat, K.P., Jin, A., Itahana, Y., Hawke, D., Kobayashi, R. and Zhang,
Y. (2003) Tumor suppressor ARF degrades B23, a nucleolar protein involved
in ribosome biogenesis and cell proliferation. Mol. Cell 12, 1151–1164.
L. Golomb et al. / FEBS Letters 588 (2014) 2571–2579 2579[118] Ayrault, O., Andrique, L., Larsen, C.J. and Seite, P. (2004) Human Arf tumor
suppressor speciﬁcally interacts with chromatin containing the promoter of
rRNA genes. Oncogene 23, 8097–8104.
[119] Ayrault, O., Andrique, L., Fauvin, D., Eymin, B., Gazzeri, S. and Seite, P. (2006)
Human tumor suppressor p14ARF negatively regulates rRNA transcription
and inhibits UBF1 transcription factor phosphorylation. Oncogene 25, 7577–
7586.
[120] Lessard, F., Morin, F., Ivanchuk, S., Langlois, F., Stefanovsky, V., Rutka, J. and
Moss, T. (2010) The ARF tumor suppressor controls ribosome biogenesis by
regulating the RNA polymerase I transcription factor TTF-I. Mol. Cell 38, 539–
550.
[121] Lessard, F., Stefanovsky, V., Tremblay, M.G. and Moss, T. (2012) The cellular
abundance of the essential transcription termination factor TTF-I regulates
ribosome biogenesis and is determined by MDM2 ubiquitinylation. Nucleic
Acids Res. 40, 5357–5367.
[122] Dai, M.S., Challagundla, K.B., Sun, X.X., Palam, L.R., Zeng, S.X., Wek, R.C. and
Lu, H. (2012) Physical and functional interaction between ribosomal protein
L11 and the tumor suppressor ARF. J. Biolog. Chem. 287, 17120–17129.
[123] Choong, M.L., Yang, H., Lee, M.A. and Lane, D.P. (2009) Speciﬁc activation of
the p53 pathway by low dose Actinomycin D: a new route to p53 based
cyclotherapy. Cell Cycle 8, 2810–2818.
[124] Drygin, D., Lin, A., Bliesath, J., Ho, C.B., O’Brien, S.E., Profﬁtt, C., Omori, M.,
Haddach, M., Schwaebe, M.K., Siddiqui-Jain, A., Streiner, N., Quin, J.E., Sanij,
E., Bywater, M.J., Hannan, R.D., Ryckman, D., Anderes, K. and Rice, W.G.
(2011) Targeting RNA polymerase I with an oral small molecule CX-5461
inhibits ribosomal RNA synthesis and solid tumor growth. Cancer Res. 71,
1418–1430.
[125] Bywater, M.J., Poortinga, G., Sanij, E., Hein, N., Peck, A., Cullinane, C., Wall, M.,
Cluse, L., Drygin, D., Anderes, K., Huser, N., Profﬁtt, C., Bliesath, J., Haddach,
M., Schwaebe, M.K., Ryckman, D.M., Rice, W.G., Schmitt, C., Lowe, S.W.,
Johnstone, R.W., Pearson, R.B., McArthur, G.A. and Hannan, R.D. (2012)
Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-
speciﬁc activation of p53. Cancer Cell 22, 51–65.
[126] Peltonen, K., Colis, L., Liu, H., Trivedi, R., Moubarek, M.S., Moore, H.M., Bai, B.,
Rudek, M.A., Bieberich, C.J. and Laiho, M. (2014) A targeting modality for
destruction of RNA polymerase I that possesses anticancer activity. Cancer
Cell 25, 77–90.
[127] Peltonen, K., Colis, L., Liu, H., Jaamaa, S., Moore, H.M., Enback, J., Laakkonen,
P., Vaahtokari, A., Jones, R.J., af Hallstrom, T.M. and Laiho, M. (2010)
Identiﬁcation of novel p53 pathway activating small-molecule compounds
reveals unexpected similarities with known therapeutic agents. PLoS One 5,
e12996.
[128] Dai, M.S., Zeng, S.X., Jin, Y., Sun, X.X., David, L. and Lu, H. (2004) Ribosomal
protein L23 activates p53 by inhibiting MDM2 function in response toribosomal perturbation but not to translation inhibition. Mol. Cell. Biol. 24,
7654–7668.
[129] Chen, D., Zhang, Z., Li, M., Wang, W., Li, Y., Rayburn, E.R., Hill, D.L., Wang, H.
and Zhang, R. (2007) Ribosomal protein S7 as a novel modulator of p53-
MDM2 interaction: binding to MDM2, stabilization of p53 protein, and
activation of p53 function. Oncogene 26, 5029–5037.
[130] Yadavilli, S., Mayo, L.D., Higgins, M., Lain, S., Hegde, V. and Deutsch, W.A.
(2009) Ribosomal protein S3: A multi-functional protein that interacts with
both p53 and MDM2 through its KH domain. DNA Repair 8, 1215–1224.
[131] Daftuar, L., Zhu, Y., Jacq, X. and Prives, C. (2013) Ribosomal proteins RPL37,
RPS15 and RPS20 regulate the Mdm2-p53-MdmX network. PLoS One 8,
e68667.
[132] Cui, D., Li, L., Lou, H., Sun, H., Ngai, S.M., Shao, G. and Tang, J. (2013) The
ribosomal protein S26 regulates p53 activity in response to DNA damage.
Oncogene [Epub ahead of print].
[133] Xiong, X., Zhao, Y., He, H. and Sun, Y. (2011) Ribosomal protein S27-like and
S27 interplay with p53-MDM2 axis as a target, a substrate and a regulator.
Oncogene 30, 1798–1811.
[134] Zhang, X., Wang, W., Wang, H., Wang, M.H., Xu, W. and Zhang, R. (2013)
Identiﬁcation of ribosomal protein S25 (RPS25)-MDM2-p53 regulatory
feedback loop. Oncogene 32, 2782–2791.
[135] Dai, M.S., Sun, X.X. and Lu, H. (2008) Aberrant expression of nucleostemin
activates p53 and induces cell cycle arrest via inhibition of MDM2. Mol. Cell.
Biol. 28, 4365–4376.
[136] Kurki, S., Peltonen, K., Latonen, L., Kiviharju, T.M., Ojala, P.M., Meek, D. and
Laiho, M. (2004) Nucleolar protein NPM interacts with HDM2 and protects
tumor suppressor protein p53 from HDM2-mediated degradation. Cancer
Cell 5, 465–475.
[137] Saxena, A., Rorie, C.J., Dimitrova, D., Daniely, Y. and Borowiec, J.A. (2006)
Nucleolin inhibits Hdm2 by multiple pathways leading to p53 stabilization.
Oncogene 25, 7274–7288.
[138] Ayrault, O., Andrique, L. and Seite, P. (2006) Involvement of the
transcriptional factor E2F1 in the regulation of the rRNA promoter. Exp.
Cell Res. 312, 1185–1193.
[139] Chan, J.C., Hannan, K.M., Riddell, K., Ng, P.Y., Peck, A., Lee, R.S., Hung, S., Astle,
M.V., Bywater, M., Wall, M., Poortinga, G., Jastrzebski, K., Sheppard, K.E.,
Hemmings, B.A., Hall, M.N., Johnstone, R.W., McArthur, G.A., Hannan, R.D.
and Pearson, R.B. (2011) AKT promotes rRNA synthesis and cooperates with
c-MYC to stimulate ribosome biogenesis in cancer. Sci. Signal. 4, ra56.
[140] Mayer, C. and Grummt, I. (2006) Ribosome biogenesis and cell growth: mTOR
coordinates transcription by all three classes of nuclear RNA polymerases.
Oncogene 25, 6384–6391.
[141] Zhang, C., Comai, L. and Johnson, D.L. (2005) PTEN represses RNA Polymerase
I transcription by disrupting the SL1 complex. Mol. Cell. Biol. 25, 6899–6911.
